Equity research projections for Regeneron Pharmaceuticals (REGN) anticipate strong long-term valuation performance through 2026, supported by robust sales of its flagship specialty therapeutics, continuous pipeline innovations in immunology and oncology, and steady institutional buying. Wall Street consensus price targets project stable percentage upside relative to historical baselines, driven by strong quarterly revenues from Eylea HD and Dupixent. While broader healthcare sector regulations, drug pricing legislative discussions, and clinical trial outcomes can introduce temporary volatility, analysts maintain an optimistic outlook anchored by the company's solid balance sheet and proven research productivity.